Login to Your Account

Harnessing the Power of Big Data

Performance in the Real World Central to New Drug's Success

By Peter Winter

Monday, August 26, 2013

Time was that getting a new medicine over the goal line equated to receiving the "green light" for approval from the FDA. In today's environment of government austerity measures and shrinking health care budgets, however, a drug's approval now only represents a "first and goal." To achieve a "touchdown" drug developers are going to have to demonstrate favorable pharmacoeconomics and real-world value for their products.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription